Abstract
The Medical Research Council Working Party on Embryonal Tumours in childhood, (Chairman: Professor R. S. Illingworth) is currently planning two therapeutic trials in Wilm's tumour (nephroblastoma) and neuroblastoma. The trial of treatment of neuroblastoma is designed to investigate whether the regression that sometimes occurs in this disease is a consequence of an immune reaction developed against the tumour and if so whether this immunity can be increased by immunotherapy. There is experimental evidence that neuroblastomas contain tumour specific antigens against which an immune reaction may be stimulated, and also that the immune system is more likely to succeed in eradicating a tumour when the number of residual malignant cells in the body is low.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
